IOL Chemicals Upgrades FY27 Guidance Following 40% Q2 Revenue Growth

Market snapshot: IOL Chemicals and Pharmaceuticals has reportedly raised its FY27 revenue growth target to over 25% from 15% and increased its capex guidance to ₹250 crore from ₹200 crore (as stated in the source alert; not independently verified). The revision follows strong financial momentum in Q2 FY27, where revenue from operations grew 40.1% YoY to ₹795 crore.

Data Snapshot

• Standalone revenue from operations reached ₹795 crore in Q2 FY27, representing a 40.1% YoY increase compared to ₹567.5 crore in Q2 FY26.
• EBITDA for Q2 FY27 expanded 79.6% YoY to ₹114.9 crore, with EBITDA margins expanding by 321 bps to 14.4%.
• Net profit after tax for Q2 FY27 rose 116.8% YoY to ₹65 crore from ₹30 crore in Q2 FY26.
• Cumulative H1 FY27 revenue from operations reached ₹1,551.3 crore, up 38.6% YoY from ₹1,119.2 crore in H1 FY26.

What's Changed

• H1 FY27 revenue from operations expanded by 38.6% YoY to ₹1,551.3 crore compared to ₹1,119.2 crore in H1 FY26.
• Q2 FY27 EBITDA margin reached 14.4%, expanding by 321 bps YoY from 11.1% in Q2 FY26.

Key Takeaways

• IOL Chemicals has reportedly revised its FY27 revenue growth target upward to over 25% and capex guidance to ₹250 crore (as stated in the source alert; not independently verified).
• The revision builds on strong recent underlying performance, with Q2 FY27 standalone net profit jumping 116.8% YoY to ₹65 crore.
• Capital deployment continues across pharmaceutical ingredients and chemical capacity expansions.

SAHI Perspective

The management decision to increase revenue and capital expenditure guidance reflects confidence in maintaining top-line expansion across core API product lines. Sustained capital investment into chemical processing assets will require disciplined capacity utilization to retain operational leverage achieved in H1 FY27.

Market Implications

Upgraded growth guidance signals healthy ongoing market demand for active pharmaceutical ingredients and industrial specialty chemicals. Higher capex commitments point to medium-term volume expansion, though execution speed will dictate margin durability.

Trading Signals

Market Bias: Bullish

Directional positive bias supported by verified Q2 FY27 standalone revenue growth of 40.1% YoY to ₹795 crore and net profit growth of 116.8% YoY to ₹65 crore.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients (APIs), Specialty Chemicals

Trigger Factors:

• Quarterly execution alignment with revised growth targets
• Commissioning timelines for ongoing capital expenditure projects
• Raw material price trends in key chemical building blocks

Time Horizon: Medium-term (3-12 months)

Industry Context

India's API and specialty chemical sectors are experiencing volume recovery led by demand in pain management and anti-diabetic therapeutic segments alongside domestic demand for chemical intermediates such as ethyl acetate.

Key Risks to Watch

• Execution and commissioning delays on expanded capex projects
• Raw material price fluctuations impacting specialty chemical margins
• Regulatory approval timelines for new active pharmaceutical ingredient facilities

Recent Developments

In October 2026, IOL Chemicals reported Q2 FY27 standalone revenue of ₹795 crore (+40.1% YoY) and net profit of ₹65 crore (+116.8% YoY). Earlier in March 2026, the company expanded its Ethyl Acetate manufacturing capacity to 1,20,000 MTPA and Acetic Anhydride capacity to 32,000 MTPA using internal accruals.

Closing Insight

With strong operational momentum established in H1 FY27, IOL Chemicals' performance will depend on executing its capital expenditure roadmap while preserving EBITDA margins in a competitive market environment.

High Performance Trading with SAHI.